Cells from patients with >10% myeloblasts showed significantly higher rates of apoptosis in CD34+ cells (presumably clonal) when compared to cells from MDS patients with lower myeloblast counts (and to healthy marrow controls); the effect of the drug combination was more profound than exposure to either DZNep or 5 AZA alone (n = 5, p = 0.04 and p = 0.001, respectively) (Figure 6E). The gene discussed is CD34; the disease is myelodysplastic syndrome.